These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22561568)

  • 1. [BRAF mutation and papillary thyroid cancer].
    Yi W; Zhong D; Zou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 37(4):370-3. PubMed ID: 22561568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
    Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.
    Kim J; Giuliano AE; Turner RR; Gaffney RE; Umetani N; Kitago M; Elashoff D; Hoon DS
    Ann Surg; 2006 Nov; 244(5):799-804. PubMed ID: 17060774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes.
    Vasko V; Hu S; Wu G; Xing JC; Larin A; Savchenko V; Trink B; Xing M
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5265-9. PubMed ID: 15998781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
    Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [BRAF gene mutation in thyroid cancer].
    Kopczyńska E; Junik R; Tyrakowski T
    Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.
    Howell GM; Carty SE; Armstrong MJ; Lebeau SO; Hodak SP; Coyne C; Stang MT; McCoy KL; Nikiforova MN; Nikiforov YE; Yip L
    Ann Surg Oncol; 2011 Dec; 18(13):3566-71. PubMed ID: 21594703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.
    Yip L; Nikiforova MN; Carty SE; Yim JH; Stang MT; Tublin MJ; Lebeau SO; Hodak SP; Ogilvie JB; Nikiforov YE
    Surgery; 2009 Dec; 146(6):1215-23. PubMed ID: 19958951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.
    Chuang TC; Chuang AY; Poeta L; Koch WM; Califano JA; Tufano RP
    Head Neck; 2010 Feb; 32(2):229-34. PubMed ID: 19626635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence and prognostic value of BRAF mutation in thyroid cancer.
    Kebebew E; Weng J; Bauer J; Ranvier G; Clark OH; Duh QY; Shibru D; Bastian B; Griffin A
    Ann Surg; 2007 Sep; 246(3):466-70; discussion 470-1. PubMed ID: 17717450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
    Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.
    Howell GM; Nikiforova MN; Carty SE; Armstrong MJ; Hodak SP; Stang MT; McCoy KL; Nikiforov YE; Yip L
    Ann Surg Oncol; 2013 Jan; 20(1):47-52. PubMed ID: 22941165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
    Wang W; Zhao W; Wang H; Teng X; Wang H; Chen X; Li Z; Yu X; Fahey TJ; Teng L
    Ann Surg Oncol; 2012 Jan; 19(1):31-6. PubMed ID: 22033631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
    Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
    Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
    Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.